These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

135 related articles for article (PubMed ID: 3472197)

  • 1. Evaluation of carbohydrate antigens 19-9 and 12-5 in patients with pancreatic cancer.
    Pasquali C; Sperti C; D'Andrea AA; Bonadimani B; Del Favero G; Petrin P; Pedrazzoli S
    Pancreas; 1987; 2(1):34-7. PubMed ID: 3472197
    [TBL] [Abstract][Full Text] [Related]  

  • 2. CA 19-9 and pancreatic adenocarcinoma.
    Safi F; Beger HG; Bittner R; Büchler M; Krautzberger W
    Cancer; 1986 Feb; 57(4):779-83. PubMed ID: 3455839
    [TBL] [Abstract][Full Text] [Related]  

  • 3. [Diagnostic importance of the tumor marker CA 19-9 in pancreatic cancer].
    Safi F; Büchler M; Schenkluhn B; Beger HG
    Dtsch Med Wochenschr; 1984 Dec; 109(49):1869-73. PubMed ID: 6209082
    [TBL] [Abstract][Full Text] [Related]  

  • 4. CA 19-9 in the differential diagnosis between pancreatic cancer and chronic pancreatitis.
    Farini R; Fabris C; Bonvicini P; Piccoli A; del Favero G; Venturini R; Panucci A; Naccarato R
    Eur J Cancer Clin Oncol; 1985 Apr; 21(4):429-32. PubMed ID: 3859414
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Carbohydrate antigen (CA 19-9)--a valuable tumor marker of pancreatic cancer.
    Lin JT; Wang TH; Sung JL; Chen DS
    Taiwan Yi Xue Hui Za Zhi; 1985 Jul; 84(7):828-35. PubMed ID: 3864924
    [No Abstract]   [Full Text] [Related]  

  • 6. Values of CA 19-9 in the serum, pure pancreatic juice, and aspirated pancreatic material in the diagnosis of malignant pancreatic tumor.
    Tatsuta M; Yamamura H; Iishi H; Ichii M; Noguchi S; Yamamoto R; Okuda S
    Cancer; 1985 Dec; 56(11):2669-73. PubMed ID: 3863691
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Serum levels of the carbohydrate antigen CA-50 in pancreatic disease.
    Blind PJ; Dahlgren ST
    Acta Chir Scand; 1987 Jan; 153(1):45-9. PubMed ID: 3472420
    [TBL] [Abstract][Full Text] [Related]  

  • 8. [The tumor markers CA 19.9, Ca 50 and CEA in the differential diagnosis of pancreatic carcinoma].
    Röthlin M; Metzger U; Joller H; Largiadèr F
    Schweiz Med Wochenschr; 1988 Jun; 118(24):924-9. PubMed ID: 2456610
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Estimation of carbohydrate antigen (CA) 19-9 levels in pure pancreatic juice of patients with pancreatic cancer.
    Nishida K; Tasaki N; Miyagawa H; Yoshikawa T; Kondo M
    Am J Gastroenterol; 1988 Feb; 83(2):126-9. PubMed ID: 3422536
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Determination of CA 19-9 antigen in serum and pancreatic juice for differential diagnosis of pancreatic adenocarcinoma from chronic pancreatitis.
    Malesci A; Tommasini MA; Bonato C; Bocchia P; Bersani M; Zerbi A; Beretta E; Di Carlo V
    Gastroenterology; 1987 Jan; 92(1):60-7. PubMed ID: 3465666
    [TBL] [Abstract][Full Text] [Related]  

  • 11. [Tumor markers of pancreatic cancer].
    Takami H; Hishinuma S; Shintoku J; Furuuchi T; Ogata Y; Abe O
    Gan To Kagaku Ryoho; 1985 Feb; 12(2):212-9. PubMed ID: 3855615
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [Comparative study of the role of CA 19-9, CA 72-4 and CEA tumor antigens in the diagnosis of pancreatic cancer and other gastrointestinal malignant diseases].
    Czakó L; Takács T; Babarczy E; Dux L; Lonovics J
    Orv Hetil; 1997 Nov; 138(47):2981-5. PubMed ID: 9432648
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Monoclonal antibody defines CA 19-9 in pancreatic juices and sera.
    Schmiegel WH; Kreiker C; Eberl W; Arndt R; Classen M; Greten H; Jessen K; Kalthoff H; Soehendra N; Thiele HG
    Gut; 1985 May; 26(5):456-60. PubMed ID: 3858206
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [Diagnostic usefulness of serum levels of pancreatic oncofetal antigen (POA) and CA 19-9 in pancreatic cancers: monitoring of postoperative recurrences].
    Takami H; Hishinuma S; Shintoku J; Ogata Y; Abe O
    Gan No Rinsho; 1985 May; 31(6 Suppl):631-7. PubMed ID: 3861883
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [The tumor-associated antigen CA 19-9 in the differential diagnosis and course control of malignancies of the pancreas and the gastrointestinal tract].
    Klapdor R; Greten H
    Dtsch Med Wochenschr; 1984 Dec; 109(50):1935-9. PubMed ID: 6210188
    [No Abstract]   [Full Text] [Related]  

  • 16. Evaluation of CA 19-9 as a serum tumour marker in pancreatic cancer.
    Haglund C; Roberts PJ; Kuusela P; Scheinin TM; Mäkelä O; Jalanko H
    Br J Cancer; 1986 Feb; 53(2):197-202. PubMed ID: 3456787
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [Importance of the tumor-associated antigen CA 19-9 in the differential diagnosis of pancreatic diseases].
    Heptner G; Domschke S; Schneider MU; Domschke W
    Dtsch Med Wochenschr; 1985 Apr; 110(16):624-8. PubMed ID: 3857159
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [The contribution of CA 19-9 in the differential diagnosis between chronic pancreatitis and cancer of the pancreas].
    Van Gossum M; Delanghe A; Gerard M; Delcourt A; Deltenre M
    Acta Gastroenterol Belg; 1987; 50(1):91-4. PubMed ID: 3480672
    [No Abstract]   [Full Text] [Related]  

  • 19. [CA-50: evaluation of a new tumor marker in the diagnosis of neoplastic pathologies of the gastrointestinal tract].
    Pecchio F; Ricci E; Rapellino M; Oliaro A; Adamo MR; Marzola G; Piantino P
    Minerva Med; 1987 Feb; 78(3):141-4. PubMed ID: 3469541
    [TBL] [Abstract][Full Text] [Related]  

  • 20. CA 19-9 and CA 50 in benign and malignant pancreatic and biliary diseases.
    Paganuzzi M; Onetto M; Marroni P; Barone D; Conio M; Aste H; Pugliese V
    Cancer; 1988 May; 61(10):2100-8. PubMed ID: 2834038
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.